Most People Who Quit Ozempic Don’t Spiral Back To Starting Weight, Study Finds

Stopping a weight-loss drug like Ozempic or Wegovy has long concerned patients worried about extra unwanted pounds returning. Now, a large real-world study from Cleveland Clinic researchers says that assumption deserves a serious second look.

Published in the journal Diabetes, Obesity and Metabolism, the study tracked nearly 8,000 adults who stopped using injectable semaglutide or tirzepatide within a year of starting. These are the drugs sold under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, a class of medications that work by mimicking a gut hormone to curb appetite and slow digestion, making it easier to eat less. On average, patients who stopped for obesity gained back less than 1% of their body weight over the following 12 months. Those taking the drugs for type 2 diabetes actually kept losing a small amount of weight. And most patients who stopped didn’t walk away from weight management entirely. More than half moved on to some other weight-loss centered activity.

That’s a notably different outcome than what clinical trials have shown. In controlled research settings, patients who stopped semaglutide regained an average of two-thirds of their lost weight. A tirzepatide trial found that only 17% of participants held onto at least 80% of their weight loss after stopping. One key difference appears to be what patients did next.

What Patients Do After Stopping GLP-1 Weight-Loss Drugs

Researchers pulled electronic health records from Cleveland Clinic facilities in Ohio and Florida, covering January 2021 through June 2025. Of the 7,938 adults in the study, all had started injectable semaglutide or tirzepatide between 2021 and 2023, then stopped between three and 12 months after starting. They averaged about 56 years of age, nearly 64% were women, and about 64% carried private health insurance.

Within one year of stopping, 20% had restarted the same medication. Another 35% moved to an alternative, including a different weight-loss drug (about 27%), structured visits with a healthcare professional focused on diet and exercise (about 14%), or bariatric surgery (less than 1%). All told, more than half of patients who stopped their original medication were actively doing something about their weight in the year that followed. That sustained effort may help explain why outcomes here looked so much better than in clinical trials, where participants had no such options once they stopped.

After Quitting, Average Weight Regain Was Surprisingly Modest

Before stopping, patients treated for obesity had lost an average of 8.4% of their body weight. Those treated for type 2 diabetes had lost an average of 4.4%. In the year after stopping, obesity patients gained back an average of just 0.5%. Diabetes patients saw an additional average loss of 1.3%.

The averages, though, cover a wide range of individual outcomes. About 55% of obesity patients gained weight in the year after stopping, and some experienced substantial regain, in a few cases exceeding 20%. Others kept losing. How someone fares often depends heavily on what treatment, if any, they pursue after stopping.

Why Diabetes Patients Fared Better After Stopping GLP-1 Drugs

Patients using these drugs for type 2 diabetes were far more likely to restart the original medication than those using them for obesity alone, at 23.5% versus 14.2%. Researchers suggest one likely explanation is insurance coverage: it is considerably broader for diabetes than for obesity, making it easier and more affordable to get back on the drug.

Among those who switched medications rather than restarting, semaglutide users most commonly moved to tirzepatide, and vice versa. Other common alternatives included phentermine and topiramate.

One more pattern worth flagging: many patients stopped before ever reaching a full therapeutic dose. Among those on semaglutide for obesity, only 27% had reached a dose of 1.7 milligrams or higher when they quit. Researchers note this mirrors findings from other large US studies and may help explain why some patients saw relatively modest weight loss before stopping in the first place.

Because the study drew from a single health system in two states, results may not reflect what happens elsewhere in the country. Reasons for stopping, whether cost, side effects, or lackluster results, were not captured in the records. And lifestyle changes patients made on their own, like eating differently or exercising more, weren’t trackable.

What the data make clear is that stopping one of these drugs is not automatically a step backward. For patients who stay engaged with their care in some form, the outcome looks far better than the clinical trial numbers would suggest.

---

Disclaimer: This article is based on an observational study and reflects associations found in a specific patient population at Cleveland Clinic facilities in Ohio and Florida. Results may not apply to all individuals. The findings do not constitute medical advice. Consult a qualified healthcare provider before making any decisions about starting, stopping, or switching medications.

---